

An Excellence Designation System (EDS) in Translational Research for Comprehensive Cancer Centers (CCC's)

Draft EDS based on stakeholder consensus

Abi Rajan (PhD candidate)

Prof. Dr. Wim van Harten (Supervisor)

Eurocan Platform WP-12
OECI Programme Symposium
ESMO 2012, Vienna
29 September 2012



Storyline

1. Why focus on Translational Research?
2. What is the need for Excellence?
3. What is the basis for & where to assess Excellence?
4. How can we assess Excellence?
5. Who will assess Excellence?
6. When will Excellence be assessed?

4 take home messages!

Why focus on Translational Research?



Earth to Mars travel time
average 150-300 days





Basic research to clinical practice
average 17 years

Source: Westfall, J. M., Mold, J., & Fagnan, L. (2007).
Practice-based research - "Blue Highways" on the
NIH roadmap. JAMA, 297(4), p. 403.

What is the need for Excellence?

- “Survival of the fittest”
- Competitive operating environment
- Excellent performance is a necessity
- Improved TR to reduce lags
- Better patient benefit & outcomes



What is the need for Excellence?

- Collaborations in TR
- Excellent Centers
- Europe wide
- Shared resources
- Formal entry
- EC support




What is the basis for & where to assess Excellence?

- OECI A&D
- Eligibility
- Expand EDS scope
- Part 1 Criteria (NKI)


4 Deliverables

- Draft (2011-12)
- Pilot (2013-14)
- Results (2015)
- Report (2016)


- Part 2 Indicators (IGR)



How can we assess excellence?



Stakeholder consensus to develop EDS- methods



Consensus findings

- Avoid bureaucracy
- Keep it slim
- Qualitative criteria
- Basic, translational & clinical
- Core & additional criteria
- Respected peer review experts
- Keep it flexible for interpretation

**LESS
IS
MORE.**

[MORE OR LESS]

DRAFT EDS - *10 themes*

1. Organizational policy & strategy
2. Financial management
3. People management
4. Collaborations
5. Research infrastructure
6. Clinical trials management
7. Innovation research outputs
8. Center profile
9. Training and development
10. Patient clinical experience

People management

Core- Mechanisms are in place to support clinicians to do lab and translational research (e.g. number of clinicians undertaking research aimed at a PhD)

Additional- Effective support for junior staff in setting project and career goals

Clinical trials management

- **Core-** Availability of clinical trials unit/translational research board to discuss clinical trials initiative and to select the most promising protocols.
- **Additional-** Percentage of patients included in clinical trials is significant

Financial management

- **Core-** Majority of the grants (at least 60%) have been obtained through a process of external peer review.
- **Additional-** Significant percentage of income has been obtained from philanthropy in the past 5 years

Who will assess excellence?

External governance
(European Academy of
Cancer Sciences)



When will Excellence be assessed?

- Open comments round (Oct 2012)
- Initial testing (Jan-March 2013)
- Pilot (May 2013- May 2014)

Other activities

- Added value of OECI A&D programme (Oct 2012-Mar 2013)

4 take home messages

- Translational “process”
- Minimised bureaucracy
- Qualitative approach
- OECI & Eurocan – institutional labels (CCC, CRC, CCCE_x)



Acknowledgements

- Eurocan Platform and OECI members
- EC
- Survey and focus group participants
- Expert group members
- NCI (TRWG)
- IGR
- NKI-AVL
- University of Twente
- ESMO

Note: The Eurocan Platform project has been funded by the EC under the FP7 programme



Emails a.rajan@nki.nl
w.v.harten@nki.nl